Latest Articles
Dostarlimab/Chemotherapy Under EMA Review for Primary Advanced/Recurrent Endometrial Cancer - OncLive
Dostarlimab/Chemotherapy Under EMA Review for Primary Advanced/Recurrent Endometrial Cancer OncLive
Published: June 24, 2024, 7 a.m.
FDA approves Keytruda plus chemo for primary advanced, recurrent endometrial carcinoma - Medical Xpress
FDA approves Keytruda plus chemo for primary advanced, recurrent endometrial carcinoma Medical Xpress
Published: June 24, 2024, 7 a.m.
Lenvatinib/Pembrolizumab Misses OS End Points, But Still Shows Activity, in Advanced Endometrial Cancer - OncLive
Lenvatinib/Pembrolizumab Misses OS End Points, But Still Shows Activity, in Advanced Endometrial Cancer OncLive
Published: June 21, 2024, 7 a.m.
FDA Approves KEYTRUDA + Chemo for Primary Advanced, Recurrent Endometrial Carcinoma - HealthDay
FDA Approves KEYTRUDA + Chemo for Primary Advanced, Recurrent Endometrial Carcinoma HealthDay
Published: June 21, 2024, 7 a.m.
Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer - Frontiers
Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer Frontiers
Published: June 20, 2024, 7 a.m.
Ankura Hospital, Bhubaneswar Launches A State-Of-The-Art Facility Specializing In Advanced Gynaecological Care For Endometriosis And Complex Laparoscopic Surgeries - Odisha Diary
Ankura Hospital, Bhubaneswar Launches A State-Of-The-Art Facility Specializing In Advanced Gynaecological Care For Endometriosis And Complex Laparoscopic Surgeries Odisha Diary
Published: June 20, 2024, 7 a.m.
FDA Approves Pembrolizumab With Chemotherapy in Advanced Endometrial Carcinoma - AJMC.com Managed Markets Network
FDA Approves Pembrolizumab With Chemotherapy in Advanced Endometrial Carcinoma AJMC.com Managed Markets Network
Published: June 17, 2024, 7 a.m.
FDA Approves Durvalumab Combination for Advanced or Recurrent Endometrial Cancer - Oncology News Central
FDA Approves Durvalumab Combination for Advanced or Recurrent Endometrial Cancer Oncology News Central
Published: June 17, 2024, 7 a.m.
FDA Approves AstraZeneca’s Imfinzi for Mismatch Repair Deficient Primary Advanced or Recurrent Endometrial Cancer - Pharmaceutical Executive
FDA Approves AstraZeneca’s Imfinzi for Mismatch Repair Deficient Primary Advanced or Recurrent Endometrial Cancer Pharmaceutical Executive
Published: June 17, 2024, 7 a.m.
Abemaciclib Plus Fulvestrant Demonstrates Activity in Advanced Endometrial Cancer - Cancer Therapy Advisor
Abemaciclib Plus Fulvestrant Demonstrates Activity in Advanced Endometrial Cancer Cancer Therapy Advisor
Published: June 11, 2024, 7 a.m.
Link copied to clipboard!